Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain
...n often appear 10 to 20 years earlier than other AD symptoms, targeting them may allow for earlier treatment of the disease. Based on this hypothesis, accera
is developing the AD drug, Ketasyn(TM) (AC-1202), which provides glucose-deprived brain cells with an alternative energy source. Ketasyn is converted ...
A Milky Alternative to Alzheimer Drug
...togenic diet sometimes used for children with severe epilepsy. Manufacturer accera
is currently hunting funding for a Phase III study, and exploring different...ned Dr. Lauren Constantini, a former Harvard scientist now with the company accera
Inc. that is developing the drug.
To stop Alzheimer's brain decay,...
Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease
BROOMFIELD, Colo., March 2 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, today launched Axona(TM) in the United States for Alzheimer's disease (AD). Axona is a first-in-class medical food for the clinical dietary...
Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease
...ona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. accera
engages in research, development and commercialization of other clinical applications for Axona.
For more information about Accera, please v...
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
... a wholly owned subsidiary and will be spun out of accera
as a stand-alone company after the completion of a $12 million series A financing round. Existing accera
investors have already committed to participate in...ompany, and the current small molecule pipeline at accera
including the preclinical compounds, AC-0523 and A...
Accera, Inc. to Present at Upcoming Investor Conferences
...d-to-moderate Alzheimer's disease. Dr. Orndorff will provide an overview of accera
and its technology pipeline and also provide an update on the successful na...ve, well-tolerated treatments. Through its proprietary scientific platform, accera
is developing therapies that address metabolic deficiencies by providing an...
Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors
... impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, accera
is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy sourc...
Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference
...f, Ph.D., Accera's founder and CEO. "As a company focused on CNS disorders, accera
is committed to improving the care and quality of life of Alzheimer's patie...ive, well-tolerated therapies. Through its proprietary scientific platform, accera
is developing products that address metabolic deficiencies associated with ...
Accera, Inc. Completes $35 Million Series C Financing
to the confidence of our investors in the accera
organization and the
potential of Axona".
Wolfga... a new
approach to neurodegenerative diseases, and accera
is a clear leader. We
are pleased to support the c...pies. Through its proprietary
scientific platform, accera
is developing products that address metabolic
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
... BROOMFIELD, Colo., Oct. 10 /PRNewswire/ -- accera
Inc., a privately
held biotechnology company focus...Ketasyn's excellent safety and
efficacy will allow accera
to make a competitive entry into the multi
billion... (AD) and age-associated memory impairment
plans to self-commercialize Ketasyn as a medical f...
Accera, Inc. to Present at the 4th Annual BIO Investor Forum
... BROOMFIELD, Colo., Oct. 4 /PRNewswire/ -- accera
Inc., a privately held
biotechnology company focused on developing novel dr... October 11 at 11:00 a.m. PDT. Dr. Orndorff will provide an overview of accera
and its technology
platform as well as a summary of the positive data from ...